Current medical guidelines for colorectal cancers, including National Comprehensive Cancer Network and European Society for Medical Oncology have recently added primary tumor location for cetuximab and panitumumab, anti-EGFR antibodies, in their recommendations for making therapeutic decisions [18,19]. This evidence concerns the gene EGFR and colorectal cancer.